Full Name
Michele Colucci JD, MFA
Job Title
Managing Partner
Company
DigitalDx Ventures
Speaker Bio
-
Michele Colucci is a venture capital thought leader, lawyer, investor, serial entrepreneur, and philanthropist. She holds multiple patents in the technology space and founded companies in the legal, technology, retail, and entertainment spaces. Her extensive experience operating in highly regulated verticals includes management, nom/gov, audit/financial, strategic, marketing, and legal. As a venture capitalist focused on AI and med tech, Colucci is committed to impacting the health field by investing in companies using technology to enable doctors and patients to make better, earlier, and less invasive diagnostic decisions.
She has board of director experience with public and private firms, past and present, including Global Indemnity Group, Biotia, Nephrosant, Optina Diagnostics, Prime Genomics, NowDx, Delphi Diagnostics, Trayt, and GLX Analytix. She has been a frequent guest lecturer at Stanford University’s School of Engineering. In 2017, Colucci was named West Coast Ambassador by the Nobel Laureate Foundation, and in 2023 she was awarded Best MedTech Investor by Silicon Valley’s Gentry Magazine. Her venture fund, DigitalDx Ventures, has been recognized in 2023 as Most Innovative ESG Initiative and Best Diversity Initiative by PEI Media. She earned her B.A. and J.D. from Georgetown University and an M.F.A from the AFI.
Key boards: Optina Diagnostics, Prime Genomics (Chair), Biotia
Michele Colucci is a venture capital thought leader, lawyer, investor, serial entrepreneur, and philanthropist. She holds multiple patents in the technology space and founded companies in the legal, technology, retail, and entertainment spaces. Her extensive experience operating in highly regulated verticals includes management, nom/gov, audit/financial, strategic, marketing, and legal. As a venture capitalist focused on AI and med tech, Colucci is committed to impacting the health field by investing in companies using technology to enable doctors and patients to make better, earlier, and less invasive diagnostic decisions.
She has board of director experience with public and private firms, past and present, including Global Indemnity Group, Biotia, Nephrosant, Optina Diagnostics, Prime Genomics, NowDx, Delphi Diagnostics, Trayt, and GLX Analytix. She has been a frequent guest lecturer at Stanford University’s School of Engineering. In 2017, Colucci was named West Coast Ambassador by the Nobel Laureate Foundation, and in 2023 she was awarded Best MedTech Investor by Silicon Valley’s Gentry Magazine. Her venture fund, DigitalDx Ventures, has been recognized in 2023 as Most Innovative ESG Initiative and Best Diversity Initiative by PEI Media. She earned her B.A. and J.D. from Georgetown University and an M.F.A from the AFI.
Key boards: Optina Diagnostics, Prime Genomics (Chair), Biotia
Speaking At
